TNFRSF11B and breast cancer: These anti-angiogenesis approaches, combined with direct anti-OPG antibody targeting, can be combined with existing chemotherapies or checkpoint inhibitors routinely used in the treatment of breast cancer for a synergistic therapeutic effect.